Centessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 52-Week High – Should You Buy?

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) shares reached a new 52-week high on Monday . The company traded as high as $25.42 and last traded at $24.8350, with a volume of 11215 shares. The stock had previously closed at $24.90.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on CNTA shares. Oppenheimer started coverage on shares of Centessa Pharmaceuticals in a research note on Friday, August 29th. They set an “outperform” rating and a $40.00 price target for the company. Guggenheim reissued a “buy” rating and issued a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Monday, October 6th. Chardan Capital restated a “buy” rating and issued a $30.00 price objective on shares of Centessa Pharmaceuticals in a research report on Tuesday, August 12th. Truist Financial initiated coverage on Centessa Pharmaceuticals in a research note on Monday, July 21st. They set a “buy” rating and a $30.00 price objective on the stock. Finally, Wells Fargo & Company initiated coverage on Centessa Pharmaceuticals in a research note on Wednesday, September 3rd. They issued an “overweight” rating and a $31.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $32.67.

Centessa Pharmaceuticals Price Performance

The company’s 50-day moving average price is $21.67 and its 200-day moving average price is $16.79. The company has a debt-to-equity ratio of 0.32, a current ratio of 10.11 and a quick ratio of 10.12. The company has a market cap of $3.20 billion, a P/E ratio of -13.34 and a beta of 1.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.03). As a group, sell-side analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

Insider Transactions at Centessa Pharmaceuticals

In related news, General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $22.41, for a total transaction of $134,460.00. Following the completion of the transaction, the general counsel owned 105,386 shares in the company, valued at approximately $2,361,700.26. This represents a 5.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CTO Tia L. Bush sold 35,000 shares of the stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $24.00, for a total transaction of $840,000.00. Following the transaction, the chief technology officer owned 121,503 shares of the company’s stock, valued at $2,916,072. The trade was a 22.36% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 145,964 shares of company stock valued at $3,169,861 over the last 90 days. 7.09% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CNTA. Bank of New York Mellon Corp acquired a new position in Centessa Pharmaceuticals during the first quarter worth $147,000. Cerity Partners LLC acquired a new stake in Centessa Pharmaceuticals in the first quarter valued at $471,000. Wildcat Capital Management LLC acquired a new stake in Centessa Pharmaceuticals in the first quarter valued at $4,053,000. Windmill Hill Asset Management Ltd acquired a new stake in Centessa Pharmaceuticals in the first quarter valued at $1,696,000. Finally, XTX Topco Ltd lifted its stake in Centessa Pharmaceuticals by 81.0% in the first quarter. XTX Topco Ltd now owns 41,057 shares of the company’s stock valued at $590,000 after acquiring an additional 18,377 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.